SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Can humans have babies in space? It may be harder than expected - 2Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- 3Iran slams UN nuclear watchdog for failing to condemn Bushehr attacks
- 4Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
- 5Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- In these U.S. groups, deaths now exceed births. What’s happening?
- Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- 2024's Hot Games: Must-Play Titles of the Year
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon
- Data centers in space: Will 2027 really be the year AI goes to orbit?
- 'No Kings' protests live updates: More than 8 million turned out across all 50 states, organizers say
- South Carolina's measles outbreak reaches 434 cases
